GLP1R and Parkinson disease: However, in the clinical PD setting it cannot be concluded that GLP1R agonists have neuroprotective effects, because there are several uncertainties and shortcomings with the exenatide study (Athauda et al., 2017): (1) It could not be determined if the effect was due to a symptomatic effect or if it represented neuroprotection.